Patents by Inventor Shai Rubnov
Shai Rubnov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931357Abstract: The present invention provides long-acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of Cariprazine or salts thereof, in a depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot compositions are preferably in the form of in-situ implants suitable for subcutaneous or intramuscular administration and provide prolonged release of the Cariprazine active ingredient and/or its metabolites desmethyl Cariprazine (DCAR) and didesmethyl Cariprazine (DDCAR) for a period of at least 4 weeks following a single administration. The present invention further provides methods of use of the depot compositions for the treatment of schizophrenia, major depressive disorder, and bipolar disorder.Type: GrantFiled: February 14, 2023Date of Patent: March 19, 2024Assignee: MAPI PHARMA LTD.Inventors: Shai Rubnov, Ehud Marom, Anna Gopin
-
Patent number: 11865213Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.Type: GrantFiled: November 24, 2021Date of Patent: January 9, 2024Assignee: MAPI PHARMA LTD.Inventors: Galina Zats, Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
-
Publication number: 20230293515Abstract: The present invention provides long-acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of Cariprazine or salts thereof, in a depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot compositions are preferably in the form of in-situ implants suitable for subcutaneous or intramuscular administration and provide prolonged release of the Cariprazine active ingredient and/or its metabolites desmethyl Cariprazine (DCAR) and didesmethyl Cariprazine (DDCAR) for a period of at least 4 weeks following a single administration. The present invention further provides methods of use of the depot compositions for the treatment of schizophrenia, major depressive disorder, and bipolar disorder.Type: ApplicationFiled: February 14, 2023Publication date: September 21, 2023Applicant: Mapi Pharma Ltd.Inventors: Shai RUBNOV, Ehud MAROM, Anna GOPIN
-
Publication number: 20230256058Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of liraglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release in the first twenty-four hours post administration. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus and Parkinson's disease.Type: ApplicationFiled: April 26, 2021Publication date: August 17, 2023Applicant: MAPI PHARMA LTD.Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
-
Publication number: 20230014750Abstract: The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.Type: ApplicationFiled: November 24, 2021Publication date: January 19, 2023Applicant: Mapi Pharma Ltd.Inventors: Galina ZATS, Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
-
Publication number: 20230000782Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.Type: ApplicationFiled: September 2, 2022Publication date: January 5, 2023Applicant: MAPI PHARMA LTD.Inventors: Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
-
Patent number: 11471421Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.Type: GrantFiled: August 28, 2017Date of Patent: October 18, 2022Assignee: MAPI PHARMA LTD.Inventors: Nadav Bleich Kimelman, Shai Rubnov, Ehud Marom
-
Publication number: 20210299057Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.Type: ApplicationFiled: August 28, 2017Publication date: September 30, 2021Applicant: MAPI PHARMA LTD.Inventors: Nadav BLEICH KIMELMAN, Shai RUBNOV, Ehud MAROM
-
Publication number: 20210283209Abstract: The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.Type: ApplicationFiled: August 9, 2017Publication date: September 16, 2021Applicant: MAPI PHARMA LTD.Inventors: Ehud MAROM, Nadav BLEICH KIMELMAN, Uri DANON, Shai RUBNOV
-
Publication number: 20210260006Abstract: The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.Type: ApplicationFiled: May 6, 2021Publication date: August 26, 2021Applicant: MAPI PHARMA LTD.Inventors: Yoram SELA, Shai RUBNOV
-
Patent number: 11026908Abstract: The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.Type: GrantFiled: July 16, 2017Date of Patent: June 8, 2021Assignee: MAPI PHARMA LTD.Inventors: Yoram Sela, Shai Rubnov
-
Publication number: 20190298675Abstract: The present invention relates to extended-release pharmaceutical compositions comprising pregabalin or a salt thereof, which are adapted to release the pregabalin active ingredient according to a dual release profile. The formulations comprise two components, the first (fast ER) providing extended-release of the active ingredient in a short controlled manner lasting from about 4 to about 6 hours, and the second (slow ER or maintenance) providing extended release of the active ingredient over a period of 24 hours. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration to a subject. The invention further relates to methods of using the pharmaceutical compositions for treating conditions and disorders which are responsive to pregabalin treatment, such as neuropathic pain associated with diabetic peripheral neuropathy (DPN), post herpetic neuralgia (PHN), epilepsy, seizures and fibromyalgia.Type: ApplicationFiled: July 16, 2017Publication date: October 3, 2019Applicants: MAPI PHARMA LTD., JIANGSU NHWA PHARMACEUTICAL CO., LTD.Inventors: Yoram SELA, Shai RUBNOV
-
Patent number: 10111867Abstract: The present invention describes a process for the synthesis of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-di-hydro-pyridin-2-one (Perampanel) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates formed and/or used in such process.Type: GrantFiled: February 17, 2015Date of Patent: October 30, 2018Assignee: MAPI PHARMA LTD.Inventors: Ehud Marom, Shai Rubnov
-
Patent number: 9994522Abstract: The present invention provides a new amorphous form of apremilast, pharmaceutical compositions comprising same, methods for preparation and use thereof in treating conditions mediated by inhibition of TNF-? production or inhibition of phosphodiesterase 4 (PDE4), e.g., psoriatic arthritis and other chronic inflammatory diseases.Type: GrantFiled: July 20, 2014Date of Patent: June 12, 2018Assignee: MAPI PHARMA LTD.Inventors: Shai Rubnov, Ehud Marom
-
Publication number: 20180008584Abstract: The present invention describes a process for the synthesis of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-di-hydro-pyridin-2-one (Perampanel) represented by the structure of formula (1), and salts thereof, especially salts with pharmaceutically acceptable acids. The present invention further relates to certain intermediates formed and/or used in such process.Type: ApplicationFiled: February 17, 2015Publication date: January 11, 2018Applicant: MAPI PHARMA LTD.Inventors: Ehud MAROM, Shai RUBNOV
-
Publication number: 20170174626Abstract: The present invention provides a new amorphous form of apremilast, pharmaceutical compositions comprising same, methods for preparation and use thereof in treating conditions mediated by inhibition of TNF-? production or inhibition of phosphodiesterase 4 (PDE4), e.g., psoriatic arthritis and other chronic inflammatory diseases.Type: ApplicationFiled: July 20, 2014Publication date: June 22, 2017Applicant: MAPI PHARMA LTD.Inventors: Shai RUBNOV, Ehud MAROM
-
Patent number: 9617241Abstract: The present invention relates to a process for the preparation of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (Efinaconazole) and intermediates used in such process.Type: GrantFiled: March 2, 2015Date of Patent: April 11, 2017Assignee: MAPI PHARMA LTD.Inventors: Anna Gopin, Shai Rubnov, Galina Zats, Ehud Marom
-
Publication number: 20160355500Abstract: The present invention relates to a process for the preparation of (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylene-1-piperidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (Efinaconazole) and intermediates used in such process.Type: ApplicationFiled: March 2, 2015Publication date: December 8, 2016Applicant: MAPI PHARMA LTD.Inventors: Anna GOPIN, Shai RUBNOV, Galina ZATS, Ehud MAROM
-
Patent number: 9206197Abstract: An amorphous form of dolutegravir sodium, pharmaceutical compositions comprising same, methods for its preparation and use thereof as an antiretroviral agent.Type: GrantFiled: September 2, 2012Date of Patent: December 8, 2015Assignee: MAPI PHARMA LTD.Inventors: Ehud Marom, Shai Rubnov
-
Patent number: RE49251Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: March 26, 2021Date of Patent: October 18, 2022Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov